What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection

The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guoli Chen, Patricia C. Tsang
Formato:	article
Lenguaje:	EN KO
Publicado:	Korean Society of Pathologists & the Korean Society for Cytopathology 2021
Materias:	Pathology RB1-214
Acceso en línea:	https://doaj.org/article/881c5ed98b374ee4ad644e5c0d5c22c4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:881c5ed98b374ee4ad644e5c0d5c22c4
record_format	dspace
spelling	oai:doaj.org-article:881c5ed98b374ee4ad644e5c0d5c22c42021-11-18T05:29:09ZWhat’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection2383-78372383-784510.4132/jptm.2021.09.01https://doaj.org/article/881c5ed98b374ee4ad644e5c0d5c22c42021-11-01T00:00:00Zhttp://www.jpatholtm.org/upload/pdf/jptm-2021-09-01.pdfhttps://doaj.org/toc/2383-7837https://doaj.org/toc/2383-7845The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue.Guoli ChenPatricia C. TsangKorean Society of Pathologists & the Korean Society for CytopathologyarticlePathologyRB1-214ENKOJournal of Pathology and Translational Medicine, Vol 55, Iss 6, Pp 421-422 (2021)
institution	DOAJ
collection	DOAJ
language	EN KO
topic	Pathology RB1-214
spellingShingle	Pathology RB1-214 Guoli Chen Patricia C. Tsang What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
description	The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue.
format	article
author	Guoli Chen Patricia C. Tsang
author_facet	Guoli Chen Patricia C. Tsang
author_sort	Guoli Chen
title	What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_short	What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_full	What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_fullStr	What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_full_unstemmed	What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_sort	what’s new in molecular genetic pathology 2021: solid tumors and ngs panel selection
publisher	Korean Society of Pathologists & the Korean Society for Cytopathology
publishDate	2021
url	https://doaj.org/article/881c5ed98b374ee4ad644e5c0d5c22c4
work_keys_str_mv	AT guolichen whatsnewinmoleculargeneticpathology2021solidtumorsandngspanelselection AT patriciactsang whatsnewinmoleculargeneticpathology2021solidtumorsandngspanelselection
_version_	1718424924031287296

What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection

Ejemplares similares